Inhibikase Therapeutics, Inc. $IKT is Kalehua Capital Management LLC’s 8th Largest Position

Kalehua Capital Management LLC lifted its position in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) by 118.4% during the 1st quarter, HoldingsChannel reports. The firm owned 3,821,890 shares of the company’s stock after buying an additional 2,071,890 shares during the period. Inhibikase Therapeutics comprises about 4.6% of Kalehua Capital Management LLC’s investment portfolio, making the stock its 8th biggest position. Kalehua Capital Management LLC’s holdings in Inhibikase Therapeutics were worth $6,421,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Sanctuary Advisors LLC purchased a new position in Inhibikase Therapeutics during the fourth quarter worth about $26,000. SG Americas Securities LLC purchased a new stake in shares of Inhibikase Therapeutics in the 1st quarter valued at about $26,000. BNP Paribas Financial Markets boosted its position in shares of Inhibikase Therapeutics by 70.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,640 shares of the company’s stock valued at $25,000 after acquiring an additional 6,458 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Inhibikase Therapeutics during the 1st quarter valued at about $28,000. Finally, XTX Topco Ltd purchased a new position in shares of Inhibikase Therapeutics during the fourth quarter worth about $42,000. Hedge funds and other institutional investors own 3.81% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Oppenheimer assumed coverage on shares of Inhibikase Therapeutics in a research note on Wednesday, June 10th. They issued an “outperform” rating and a $5.00 target price on the stock. LADENBURG THALM/SH SH raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, July 13th. Wall Street Zen upgraded shares of Inhibikase Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Friday, July 17th. Four investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Inhibikase Therapeutics currently has a consensus rating of “Buy” and an average price target of $5.40.

Inhibikase Therapeutics Price Performance

Shares of IKT opened at $2.33 on Monday. Inhibikase Therapeutics, Inc. has a 1 year low of $1.33 and a 1 year high of $2.53. The stock has a 50 day simple moving average of $1.86 and a two-hundred day simple moving average of $1.81. The firm has a market cap of $307.63 million, a P/E ratio of -5.42 and a beta of 0.94.

Inhibikase Therapeutics (NASDAQ:IKT) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). On average, equities analysts anticipate that Inhibikase Therapeutics, Inc. will post -0.42 earnings per share for the current year.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.